Non-obese patients with type 2 diabetes and prediabetic subjects: Distinct phenotypes requiring special diabetes treatment and (or) prevention?

Applied Physiology, Nutrition and Metabolism

Volumn 32, Issue 5, 2007, Pages 912-920

  Vaag, Allan ^a   Lund, Søren S ^b  

^a STENO DIABETES CENTER   (Denmark)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Non obese; Pathophysiology; Prevention; Treatment; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT;

HUMAN; IMPAIRED GLUCOSE TOLERANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PHENOTYPE; PREDIABETIC STATE;

EID: 36148939069     PISSN: 17155312     EISSN: None     Source Type: Journal    
DOI: 10.1139/H07-100     Document Type: Review

References (51)

1. Adlerberth, A.M., Rosengren, A., and Wilhelmsen, L. 1998. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care, 21: 539-545. doi:10.2337/diacare.21.4.539. PMID:9571339.
2. Buemann, B., Sorensen, T.I., Pedersen, O., Black, E., Holst, C., Toubro, S., et al. 2005. Lower-body fat mass as an independent marker of insulin sensitivity - the role of adiponectin. Int. J. Obes. (Lond), 29: 624-631. doi:10.1038/sj.ijo.0802929. PMID:15824752.
3. Butler, A.E., Janson, J., Soeller, W.C., and Butler, P.C. 2003. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes, 52: 2304-2314. doi:10.2337/diabetes. 52.9.2304. PMID:12941770.
4. Chang, S.A., Kim, H.S., Yoon, K.H., Ko, S.H., Kwon, H.S., Kim, S.R., et al. 2004. Body mass index is the most important determining factor for the degree of insulin resistance in non-obese type 2 diabetic patients in Korea. Metabolism, 53: 142-146. doi:10.1016/S0026-0495(03)00314-7. PMID:14767863.
5. Dalton, M., Cameron, A.J., Zimmet, P.Z., Shaw, J.E., Jolley, D., Dunstan, D.W., et al. 2003. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J. Intern. Med. 254: 555-563. doi:10.1111/j.1365-2796.2003.01229. x. PMID:14641796.
6. Donnelly, L.A., Doney, A.S., Hattersley, A.T., Morris, A.D., and Pearson, E.R. 2006. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet. Med. 23: 128-133. doi:10.1111/j.1464-5491.2005.01755.x. PMID:16433709.
7. Fernandez-Castaner, M., Biarnes, J., Camps, I., Ripolles, J., Gomez, N., and Soler, J. 1996. Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus. Diabet. Med. 13: 953-959. doi:10.1002/(SICI)1096-9136(199611) 13:11<953::AID-DIA257>3.0.CO;2-V.PMID: 8946153.
8. Garancini, M.P., Calori, G., Ruotolo, G., Manara, E., Izzo, A., Ebbli, E., et al. 1995. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia, 38: 306-313. PMID:7758877.
9. Graham, T.E., Yang, Q., Bluher, M., Hammarstedt, A., Ciaraldi, T.P., Henry, R.R., et al. 2006. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354: 2552-2563. doi:10.1056/NEJMoa054862. PMID:16775236.
10. Hermann, T.S., Rask-Madsen, C., Ihlemann, N., Dominguez, H., Jensen, C.B., Storgaard, H., et al. 2003. Normal insulin-stimulated endothelial function and impaired insulin-stimulated muscle glucose uptake in young adults with low birth weight. J. Clin. Endocrinol. Metab. 88: 1252-1257. doi:10.1210/jc.2002-021550. PMID:12629115.
11. Hollenbeck, C.B., Chen, Y.D., and Reaven, G.M. 1984. A comparison of the relative effects of obesity and non-insulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilization. Diabetes, 33: 622-626. doi:10.2337/diabetes.33.7.622. PMID:6376218.
12. Holman, R.R. 2006. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metab. Clin. Exp. 55(Suppl. 1): S2-S5. doi:10.1016/j.metabol.2006.02.006. PMID:16631806.
13. Inzucchi, S.E. 2002. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 287: 360-372. doi:10.1001/jama.287.3.360. PMID:11790216.
14. Jensen, C.B., Storgaard, H., Dela, F., Holst, J.J., Madsbad, S., and Vaag, A.A. 2002. Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes, 51: 1271-1280. doi:10.2337/diabetes.51.4.1271. PMID:11916955.
15. King, H., Aubert, R.E., and Herman, W.H. 1998. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21: 1414-1431. doi:10.2337/diacare.21.9.1414. PMID:9727886.
16. Kirpichnikov, D., McFarlane, S.I., and Sowers, J.R. 2002. Metformin: an update. Ann. Intern. Med. 137: 25-33. PMID:12093242.
17. Lund, S.S., Tarnow, L., Stehouwer, C.D., Schalkwijk, C.G., Frandsen, M., Smidt, U.M., et al. 2007. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes. Metab. 9: 394-407. doi:10.1111/j.1463-1326.2007.00713.x. PMID:17391168.
18. Mamputu, J.C., Wiernsperger, N.F., and Renier, G. 2003. Anti-atherogenic properties of metformin: the experimental evidence. Diabetes Metab. 29: S671-S676.
19. Manson, J.E., Colditz, G.A., Stampfer, M.J., Willett, W.C., Krolewski, A., Rosner, B., et al. 1991. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch. Intern. Med. 151: 1141-1148. doi.10.1001/archinte.151.6.1141. PMID:2043016.
20. Mohan, V., and Deepa, R. 2006. Adipocytokines and the expanding 'Asian Indian Phenotype'. J. Assoc. Physicians India, 54: 685-686. PMID:17212014.
21. Mohan, V., Vijayaprabha, R., Rema, M., Premalatha, G., Poongothai, S., Deepa, R., et al. 1997. Clinical profile of lean NIDDM in South India. Diabetes Res. Clin. Pract. 38: 101-108. doi:10.1016/S0168-8227(97)00088-0. PMID:9483373.
22. Mojiminiyi, O.A., Abdella, N.A., Al, A.M., and Ben, N.A. 2007. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int. J. Obes. (Lond), 31: 213-220. doi:10.1038/sj.ijo.0803355. PMID:16755284.
23. Nakagami, T., Qiao, Q., Carstensen, B., Nøhr-Hansen, C., Hu, G., Tuomilehto, J., et al. 2003. Age, body mass index and type 2 diabetes-associations modified by ethnicity. Diabetologia, 46: 1063-1070. PMID:12827246.
24. Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., et al. 2006. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 49: 1711-1721. doi:10.1007/s00125-006-0316-2. PMID:16802130.
25. Ong, C.R., Molyneaux, L.M., Constantino, M.I., Twigg, S.M., and Yue, D. K. 2006. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care, 29: 2361-2364. doi:10.2337/dc06-0827. PMID:17065668.
26. Ozanne, S.E., Jensen, C.B., Tingey, K.J., Storgaard, H., Madsbad, S., and Vaag, A.A. 2005. Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia, 48: 547-552. doi:10.1007/s00125-005-1669-7. PMID:15729577.
27. Pan, X.R., Li, G.W., Hu, Y.H., Wang, J.X., Yang, W.Y., An, Z.X., et al. 1997. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care, 20: 537-544. doi: 10.2337/diacare.20.4.537. PMID:9096977.
28. Poulsen, P., Vaag, A.A., Kyvik, K.O., Moller, J.D., and Beck-Nielsen, H. 1997. Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia, 40: 439-446. doi:10.1007/ s001250050698. PMID:9112021.
29. Poulsen, P., Kyvik, K.O., Vaag, A., and Beck-Nielsen, H. 1999. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance - a population-based twin study. Diabetologia, 42: 139-145. doi:10.1007/s001250051131. PMID:10064092.
30. Rasmussen, E.L., Malis, C., Jensen, C.B., Jensen, J.E., Storgaard, H., Poulsen, P., et al. 2005. Altered fat tissue distribution in young adult men who had low birth weight. Diabetes Care, 28: 151-153. doi:10.2337/diacare. 28.1.151. PMID:15616250.
31. Ratner, R.E. 2006. An update on the Diabetes Prevention Program. Endocr. Pract. 12(Suppl. 1): 20-24. PMID:16627375.
32. Ritzel, R.A., Butler, A.E., Rizza, R.A., Veldhuis, J.D., and Butler, P.C. 2006. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care, 29: 717-718. doi:10.2337/diacare. 29.03.06.dc05-1538. PMID:16505537.
33. Saxena, R., Gianniny, L., Burtt, N.P., Lyssenko, V., Giuducci, C., Sjogren, M., et al. 2006. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes, 55: 2890-2895. doi:10.2337/db06-0381. PMID:17003358.
34. Skarfors, E.T., Selinus, K.I., and Lithell, H.O. 1991. Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ, 303: 755-760. PMID:1932936.
35. Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., et al. 2007. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 445: 881-885. doi:10.1038/nature05616. PMID:17293876.
36. Tuomi, T. 2005. Type 1 and type 2 diabetes: what do they have in common? Diabetes, 54(Suppl. 2): S40-S45. doi:10.2337/diabetes.54.suppl_2.S40. PMID:16306339.
37. Turner, R.C., Cull, C.A., Stratton, I.M., Manley, S.E., Kohner, E.M., Matthews, D.R., et al. 1995. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes, 44: 1249-1258. PMID:7589820.
38. Turner, R., Stratton, I., Horton, V., Manley, S., Zimmet, P., Mackay, I.R., et al. 1997. UKPDS 25: autoantibodies to isletcell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet, 350: 1288-1293. doi:10.1016/S0140-6736(97)03062-6. PMID:9357409.
39. UK Prospective Diabetes Study Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352: 854-865. doi:10.1016/S0140-6736(98)07037-8. PMID:9742977.
40. Vaag, A. 1999. On the pathophysiology of late onset non-insulin dependent diabetes mellitus: current controversies and new insights. Dan. Med. Bull. 46:197-234. PMID:10421979.
41. Vaag, A., Henriksen, J.E., and Beck-Nielsen, H. 1992. Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 89: 782-788. PMID:1541672.
42. Vaag, A., Henriksen, J.E., Madsbad, S., Holm, N., and Beck-Nielsen, H. 1995. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J. Clin. Invest. 95: 690-698. PMID:7860750.
43. Vaag, A.A., Holst, J.J., Volund, A., and Beck-Nielsen, H.B. 1996. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur. J. Endocrinol. 135: 425-432. PMID:8921824.
44. Vaag, A., Jensen, C.B., Poulsen, P., Brons, C., Pilgaard, K., Grunnet, L., et al. 2006. Metabolic aspects of insulin resistance in individuals born small for gestational age. Horm. Res. 65(Suppl. 3): 137-143. doi: 10.1159/000091519. PMID:16612127.
45. Willett, W.C., Dietz, W.H., and Colditz, G.A. 1999. Guidelines for healthy weight. N. Engl. J. Med. 341: 427-434. doi: 10.1056/ NEJM199908053410607. PMID:10432328.
46. World Health Organization. 1999. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. WHO/NCD/NCS, 99.2: 1-59.
47. World Health Organization. 2003. Diet, nutrition and the prevention of chronic diseases. WHO Tech. Rep. Ser. 916: 1-148.
48. Yajnik, C.S., and Yudkin, J.S. 2004. The Y-Y paradox. Lancet, 363: 163. doi:10.1016/S0140-6736(03)15269-5. PMID:14726172.
49. Yajnik, C.S., Lubree, H.G., Rege, S.S., Naik, S.S., Deshpande, J.A., Deshpande, S.S., et al. 2002. Adiposity and hyperinsulinemia in Indians are present at birth. J. Clin. Endocrinol. Metab. 87: 5575-5580. doi:10.1210/jc.2002-020434. PMID:12466355.
50. Yki-Jarvinen, H., Ryysy, L., Nikkila, K., Tulokas, T., Vanamo, R., and Heikkila, M. 1999. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 130: 389-396. PMID:10068412.
51. Yusuf, S., Hawken, S., Ounpuu, S., Bautista, L., Franzosi, M.G., Commerford, P., et al. 2005. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet, 366: 1640-1649. doi:10.1016/S0140-6736(05)67663-5. PMID:16271645.